Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LATUDA

« Back to Dashboard
Latuda is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lurasidone hydrochloride profile page.

Summary for Tradename: LATUDA

Suppliers: see list1

Pharmacology for Tradename: LATUDA

Clinical Trials for: LATUDA

Lurasidone Low-Dose - High-Dose Study Study
Status: Completed Condition: Schizophrenia

Lurasidone Effects on Tissue Glutamate in Schizophrenia
Status: Recruiting Condition: Schizophrenia; Schizoaffective Disorder

Lurasidone Pediatric Autism Study
Status: Completed Condition: Autism

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
Status: Completed Condition: Schizophrenia

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old
Status: Not yet recruiting Condition: Mania; Bipolar I; Bipolar II; Bipolar Spectrum Disorder; Bipolar Disorder

Pediatric Schizophrenia Efficacy and Safety Study
Status: Recruiting Condition: Schizophrenia

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Completed Condition: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS; Autistic Disorder; Asperger Syndrome; Child Development Disorders, Pervasive; Bipolar I Disorder; Bipolar II Disorder; Mood Disorder NOS; Severe Major Depression With Psychotic Features; Single Episode Major Depression Without Psychotic Symptoms; Severe Mood Disorder With Psychotic Features

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Status: Completed Condition: Schizophrenia; Schizoaffective Disorder

Lurasidone Pediatric Pharmacokinetics Study
Status: Completed Condition: Schizophrenia; Autism

Lurasidone and Cognition in Bipolar I Disorder
Status: Recruiting Condition: Bipolar I Disorder

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
lurasidone hydrochloride
TABLET;ORAL200603-005Jul 12, 2013RXNo<disabled><disabled>
Sunovion Pharms Inc
lurasidone hydrochloride
TABLET;ORAL200603-002Oct 28, 2010RXNo<disabled><disabled>
Sunovion Pharms Inc
lurasidone hydrochloride
TABLET;ORAL200603-001Oct 28, 2010RXYes<disabled><disabled>
Sunovion Pharms Inc
lurasidone hydrochloride
TABLET;ORAL200603-003Dec 7, 2011RXNo8,729,085<disabled>Y<disabled>
Sunovion Pharms Inc
lurasidone hydrochloride
TABLET;ORAL200603-001Oct 28, 2010RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LATUDA

Drugname Dosage Strength RLD Submissiondate
lurasidone hydrochlorideTablets20 mg, 40 mg, 60 mg, 80 mg, and 120 mgLatuda10/28/2014
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn